Glucagon-like peptide-1 agonists for weight loss
Pro Research Analysisby 
Searched over 200M research papers
GLP-1 Agonists for Weight Loss: Efficacy in Obesity and Overweight
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become a leading option for weight loss in adults with obesity or overweight, both with and without diabetes. These medications, originally developed for type 2 diabetes, are now widely recognized for their ability to help people lose significant amounts of weight and improve related health outcomes Moiz2025Liu2023Ard2021+3 MORE.
Weight Loss Outcomes with GLP-1 Agonists
Multiple large-scale analyses show that GLP-1 RAs consistently lead to significant weight loss compared to placebo. In adults without diabetes, semaglutide (2.4 mg weekly) can result in up to 13.9% weight loss after about 68 weeks, while liraglutide (3.0 mg daily) achieves up to 5.8% weight loss after 26 weeks Moiz2025Liu2023. Newer agents and co-agonists, such as tirzepatide and retatrutide, have demonstrated even greater effects, with retatrutide (12 mg weekly) producing up to 22.1% weight loss after 48 weeks and tirzepatide (15 mg weekly) up to 17.8% after 72 weeks Moiz2025Xie2024Zhang2025. These results are supported by meta-analyses and network reviews, which consistently rank retatrutide and tirzepatide as the most effective for weight reduction among GLP-1-based therapies Xie2024Zhang2025.
Additional Health Benefits Beyond Weight Loss
GLP-1 RAs not only reduce body weight but also improve other health markers. They lower body mass index (BMI), waist circumference, and blood pressure, and improve lipid profiles, including reductions in total cholesterol, LDL, and triglycerides, while increasing HDL Liu2023Ansari2023Riedinger2024. These changes contribute to a lower risk of cardiovascular disease and other obesity-related complications Ansari2023Giannakogeorgou2024Riedinger2024.
Efficacy in Different Populations
The weight loss effects of GLP-1 RAs are seen in both people with and without diabetes, though the impact is generally greater in those without diabetes and in individuals with higher baseline BMI or longer treatment duration Xie2024Zhang2025. The benefits are robust across different races and body types, and longer treatment cycles tend to yield better results .
Safety and Side Effects
The most common side effects of GLP-1 RAs are gastrointestinal, such as nausea, vomiting, diarrhea, and constipation. These are usually mild and occur early in treatment, often improving over time Moiz2025Ard2021Ansari2023+1 MORE. Serious adverse events and treatment discontinuation due to side effects are rare, and there is no significant increase in hypoglycemic events Moiz2025Xie2024Ansari2023. Active management of side effects can help prevent discontinuation .
Mechanism of Action
GLP-1 RAs promote weight loss by reducing appetite, slowing gastric emptying, and increasing feelings of fullness after eating Ard2021Baggio2020Giannakogeorgou2024. These mechanisms help people eat less and maintain weight loss over time. Some agents, like tirzepatide and retatrutide, also target additional pathways, further enhancing weight loss Xie2024Zhang2025Baggio2020.
Conclusion
GLP-1 receptor agonists are highly effective for weight loss in adults with obesity or overweight, with or without diabetes. Newer agents and co-agonists offer even greater efficacy, and all GLP-1 RAs provide additional health benefits such as improved blood pressure and cholesterol. The main side effects are gastrointestinal and usually manageable. These medications represent a major advance in obesity treatment, offering hope for sustained weight loss and improved health outcomes Moiz2025Xie2024Liu2023+6 MORE.
Sources and full results
Most relevant research papers on this topic
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes
GLP-1 RAs and co-agonists are effective for weight loss in adults with overweight or obesity and without diabetes, with gastrointestinal-related safety concerns being the most common.
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
New co-agonists with robust efficacy should prove superior to GLP-1R agonists alone in treating metabolic disorders, potentially outperforming bariatric surgery.
Efficacy and safety of glucagon-like-peptide-1 receptor agonists on body weight and cardiometabolic parameters in individuals with obesity and without diabetes: A systematic review and meta-analysis.
GLP-1 RAs effectively promote weight loss and improve cardiovascular health in obese individuals without diabetes, but may increase the risk of gastrointestinal adverse events.
DOI